Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate
Article first published online: 23 DEC 2001
British Journal of Dermatology
Volume 144, Issue 3, pages 587–589, February 2001
How to Cite
Ogilvie, A.L.J., Antoni, C., Dechant, C., Manger, B., Kalden, J.R., Schuler, G. and Lüftl, M. (2001), Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. British Journal of Dermatology, 144: 587–589. doi: 10.1046/j.1365-2133.2001.04089.x
- Issue published online: 23 DEC 2001
- Article first published online: 23 DEC 2001
- Accepted for publication 30 October 2000
- antitumour necrosis factor-α antibody;
- Psoriasis Area and Severity Index;
- psoriatic arthritis;
- tumour necrosis factor-α
Background In inflamed skin, keratinocytes and inflammatory cells both produce large amounts of tumour necrosis factor (TNF) -α, a cytokine with broad effects that are relevant to inflammation. Blockade of this proinflammatory cytokine by a monoclonal anti-TNF-α antibody might be effectively used in the treatment of inflammatory skin diseases.
Objectives To gather information about the efficacy of an anti-TNF-α antibody (infliximab) in the treatment of skin lesions of psoriatic arthritis.
Methods Six patients with progressive joint disease and psoriatic skin lesions unresponsive to methotrexate therapy were treated with anti-TNF-α antibody. The Psoriasis Area and Severity Index was determined before and 10 weeks after initiation of therapy.
Results Improvement of psoriatic skin lesions was observed in all patients. In addition, a marked improvement of the joint disease was noted.
Conclusions Therapy with anti-TNF-α antibody may be an effective treatment regimen for both psoriatic arthritis and psoriatic skin lesions.